Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (29849) 29849
Book Review (5741) 5741
Publication (2420) 2420
Newsletter (2047) 2047
Newspaper Article (1888) 1888
Book Chapter (326) 326
Trade Publication Article (181) 181
Magazine Article (96) 96
Book / eBook (93) 93
Web Resource (81) 81
Conference Proceeding (77) 77
Dissertation (18) 18
Transcript (18) 18
Reference (4) 4
Paper (3) 3
Data Set (2) 2
Report (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22367) 22367
humans (21394) 21394
lymphomas (14300) 14300
male (11282) 11282
female (10590) 10590
oncology (9815) 9815
middle aged (9097) 9097
hematology (8397) 8397
cancer (7720) 7720
aged (7696) 7696
adult (7506) 7506
lymphoma (7088) 7088
chemotherapy (5553) 5553
prognosis (4417) 4417
non-hodgkins-lymphoma (4165) 4165
b-cell lymphoma (3994) 3994
pathology (3917) 3917
research (3881) 3881
care and treatment (3863) 3863
non-hodgkin's lymphomas (3745) 3745
leukemia (3587) 3587
aged, 80 and over (3336) 3336
rituximab (3155) 3155
diagnosis (3008) 3008
lymphoma, large b-cell, diffuse - pathology (2990) 2990
medicine & public health (2947) 2947
antineoplastic combined chemotherapy protocols - therapeutic use (2926) 2926
hemic and lymphatic diseases (2921) 2921
animals (2801) 2801
treatment outcome (2770) 2770
adolescent (2707) 2707
analysis (2676) 2676
abridged index medicus (2609) 2609
immunohistochemistry (2586) 2586
tumors (2539) 2539
expression (2500) 2500
health aspects (2343) 2343
patients (2302) 2302
survival (2175) 2175
retrospective studies (2134) 2134
disease (2104) 2104
genetic aspects (2090) 2090
lymphoma, large b-cell, diffuse - drug therapy (2057) 2057
risk factors (1966) 1966
young adult (1949) 1949
lymphocytes (1912) 1912
transplantation (1907) 1907
medical research (1887) 1887
gene expression (1858) 1858
t cells (1834) 1834
immunology (1760) 1760
follicular lymphoma (1711) 1711
biopsy (1705) 1705
chronic lymphocytic-leukemia (1674) 1674
immune system diseases (1658) 1658
lymphocytes b (1630) 1630
apoptosis (1616) 1616
therapy (1612) 1612
child (1576) 1576
diffuse large b-cell lymphoma (1572) 1572
lymphoma, b-cell - pathology (1560) 1560
lymphoma, large b-cell, diffuse - genetics (1556) 1556
diagnosis, differential (1549) 1549
mutation (1511) 1511
antineoplastic agents - therapeutic use (1501) 1501
article (1465) 1465
classification (1441) 1441
proteins (1403) 1403
mice (1385) 1385
disease-free survival (1360) 1360
stem cells (1359) 1359
bone marrow (1337) 1337
neoplasm staging (1335) 1335
medical prognosis (1328) 1328
immunotherapy (1322) 1322
medicine (1314) 1314
cell biology (1274) 1274
lymphoma, large b-cell, diffuse - diagnosis (1273) 1273
development and progression (1266) 1266
cancer therapies (1247) 1247
lymphoma - pathology (1237) 1237
cell line, tumor (1233) 1233
survival analysis (1224) 1224
medicine, experimental (1186) 1186
clinical trials (1184) 1184
non-hodgkin lymphoma (1179) 1179
lymphoma, non-hodgkin - pathology (1145) 1145
drug therapy (1116) 1116
genes (1116) 1116
non-hodgkin's lymphoma (1106) 1106
antineoplastic combined chemotherapy protocols - administration & dosage (1096) 1096
flow cytometry (1069) 1069
cyclophosphamide - administration & dosage (1062) 1062
follow-up studies (1061) 1061
studies (1053) 1053
survival rate (1053) 1053
immunophenotyping (1045) 1045
antigens (1041) 1041
non-hodgkin-lymphoma (1038) 1038
case report (1031) 1031
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (63) 63
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Circulation Desk (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
UofT Schools - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33817) 33817
German (172) 172
Japanese (150) 150
French (127) 127
Russian (56) 56
Chinese (51) 51
Italian (41) 41
Spanish (33) 33
Korean (27) 27
Polish (19) 19
Turkish (9) 9
Danish (8) 8
Romanian (8) 8
Portuguese (5) 5
Dutch (4) 4
Hungarian (4) 4
Bulgarian (3) 3
Czech (3) 3
Hebrew (2) 2
Croatian (1) 1
Finnish (1) 1
Latvian (1) 1
Manx (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
by Kurtz, David M and Green, Michael R and Bratman, Scott V and Scherer, Florian and Liu, Chih Long and Kunder, Christian A and Takahashi, Kazuhiro and Glover, Cynthia and Keane, Colm and Kihira, Shingo and Visser, Brendan and Callahan, Jason and Kong, Katherine A and Faham, Malek and Corbelli, Karen S and Miklos, David and Advani, Ranjana H and Levy, Ronald and Hicks, Rodney J and Hertzberg, Mark and Ohgami, Robert S and Gandhi, Maher K and Diehn, Maximilian and Alizadeh, Ash A
Blood, ISSN 0006-4971, 06/2015, Volume 125, Issue 24, pp. 3679 - 3687
Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-cell lymphoma (DLBCL) patients achieving remission. Detection of... 
DLBCL | POSITRON-EMISSION-TOMOGRAPHY | HODGKINS-LYMPHOMA | CIRCULATING TUMOR-CELLS | RESIDUAL DISEASE DETECTION | DNA | RESPONSE ASSESSMENT | HEMATOLOGY | EXPRESSION | CHEMOTHERAPY | PET | Prospective Studies | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Male | Positron-Emission Tomography | Immunoglobulins - genetics | Lymphoma, Large B-Cell, Diffuse - blood | L-Lactate Dehydrogenase - blood | Immunoglobulins - blood | Female | High-Throughput Nucleotide Sequencing | Lymphoma, Large B-Cell, Diffuse - genetics | Index Medicus | Abridged Index Medicus | Plenary Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: Results from a French multicenter clinical trial
by Rossille, D and Rossille, D and Gressier, M and Damotte, D and Maucort-Boulch, D and Pangault, C and Semana, G and Le Gouill, S and Haioun, C and Tarte, K and Lamy, T and Milpied, N and Fest, T and Damaj, G and Clavert, A and Al Jijakli, A and Banos, A and Dutel, J.-L and Deconinck, E and Rodon, P and Bouabdallah, K and Soubeyran, P and Choufi, B and Maakaroun, A and Tournilhac, O and Fleury, J and Gressin, R and Maisonneuve, H and Laribi, K and Solal-Celigny, P and Moreau, P and Rossi, J.-F and Cartron, G and Morineau, N and Harousseau, J.L and Jourdan, E and Alexis, M and Dreyfus, F and Delwail, V and Cornillon, J and Garidi, R and Gyan, E and Colombat, P and Godemer, P and Grp Ouest-Est Leucemies Autres Mal and Groupe Ouest-Est des Leucémies et Autres Maladies du Sang and for the Groupe Ouest-Est des Leucémies et Autres Maladies du Sang
Leukemia, ISSN 0887-6924, 12/2014, Volume 28, Issue 12, pp. 2367 - 2375
The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient... 
CONSOLIDATION | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | IMMUNOTHERAPY | R-CHOP | VINCRISTINE | DOXORUBICIN | MECHANISMS | HODGKIN-LYMPHOMA | HEMATOLOGY | EXPRESSION | CHEMOTHERAPY | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prognosis | Follow-Up Studies | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Male | Treatment Outcome | Disease Progression | Lymphoma, Large B-Cell, Diffuse - mortality | Young Adult | Clinical Trials, Phase III as Topic | B7-H1 Antigen - blood | Lymphoma, Large B-Cell, Diffuse - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Intention to Treat Analysis | Adult | Female | France | Neoplasm Staging | Development and progression | Lymphomas | Genetic aspects | Blood diseases | Cell death | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
by Philippe Armand and Arnon Nagler and Edie A. Weller and Steven M. Devine and David E. Avigan and Yi-Bin Chen and Mark S. Kaminski and H. Kent Holland and Jane N. Winter and James R. Mason and Joseph W. Fay and David A. Rizzieri and Chitra M. Hosing and Edward D. Ball and Joseph P. Uberti and Hillard M. Lazarus and Markus Y. Mapara and Stephanie A. Gregory and John M. Timmerman and David Andorsky and Reuven Or and Edmund K. Waller and Rinat Rotem-Yehudar and Leo I. Gordon
Journal of Clinical Oncology, ISSN 0732-183X, 11/2013, Volume 31, Issue 33, pp. 4199 - 4206
Purpose The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune... 
SALVAGE CHEMOTHERAPY | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | SAFETY | IMMUNOTHERAPY | NON-HODGKINS-LYMPHOMA | MONOCLONAL-ANTIBODY | HEMATOLOGIC MALIGNANCIES | PD-1 | RECONSTITUTION | MARROW TRANSPLANTATION | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fatigue - etiology | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Transplantation, Autologous | Neutropenia - etiology | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Aged, 80 and over | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Chile | Antibodies, Monoclonal - immunology | Immune Tolerance - drug effects | Drug Administration Schedule | Treatment Outcome | Combined Modality Therapy | India | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - blood | Lymphocyte Count | Aged | Hematopoietic Stem Cell Transplantation - methods | Israel | Programmed Cell Death 1 Receptor - immunology | Index Medicus | Hema13 | Hema16 | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Modulation the expression of natural killer cell activating receptor (NKp44) in the peripheral blood of diffuse large B-cell lymphoma patients and the correlation with clinic pathological features
by Essa, Enas Said and Tawfeek, Gehan Abd-Elfatah and El Hassanin, Suzan Ahmed and Emara, Khloud Gamal Mohammed
Clinical Immunology, ISSN 1521-6616, 03/2018, Volume 188, pp. 38 - 44
NK cell activation is one strategy to improve the immunotherapy of non-Hodgkin's lymphoma. So, we aimed to investigate expression of Natural killer cell... 
NK activation | DLBCL | Immunomodulation | NKp44 | GROWTH | CHRONIC LYMPHOCYTIC-LEUKEMIA | IMMUNOLOGY | Leukocytes, Mononuclear - metabolism | Natural Cytotoxicity Triggering Receptor 2 - blood | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Cells, Cultured | Male | Lymphoma, Large B-Cell, Diffuse - metabolism | Young Adult | Flow Cytometry | Leukocytes, Mononuclear - immunology | Aged, 80 and over | Killer Cells, Natural - immunology | Lymphocyte Count | Lymphoma, Large B-Cell, Diffuse - immunology | Natural Cytotoxicity Triggering Receptor 2 - metabolism | Adult | Female | Aged | Killer Cells, Natural - metabolism | Natural Cytotoxicity Triggering Receptor 2 - immunology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP
by Li, Zhi-Ming and Huang, Jia-Jia and Xia, Yi and Sun, Jian and Huang, Ying and Wang, Yu and Zhu, Ying-Jie and Li, Ya-Jun and Zhao, Wei and Wei, Wen-Xiao and Lin, Tong-Yu and Huang, Hui-Qiang and Jiang, Wen-Qi
PLoS ONE, ISSN 1932-6203, 07/2012, Volume 7, Issue 7, pp. e41658 - e41658
Background: Recent research has shown a correlation between immune microenvironment and lymphoma biology. This study aims to investigate the prognostic... 
SURVIVAL | LYMPHOPENIA | ABSOLUTE MONOCYTE | PROGNOSTIC-FACTOR | RESPONSE CRITERIA | MULTIDISCIPLINARY SCIENCES | TUMOR | NON-HODGKIN-LYMPHOMA | COUNT | EXPRESSION | CHEMOTHERAPY | Doxorubicin - therapeutic use | Multivariate Analysis | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prognosis | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Treatment Outcome | Cyclophosphamide - therapeutic use | Lymphoma, Large B-Cell, Diffuse - diagnosis | Lymphoma, Large B-Cell, Diffuse - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Monocytes - pathology | Vincristine - therapeutic use | Female | ROC Curve | Aged | Leukocyte Count | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Care and treatment | Anthracyclines | Cyclophosphamide | Corticosteroids | Lymphocytes | Prednisone | Non-Hodgkin's lymphomas | Therapy | Working groups | Laboratories | Cytotoxicity | Oncology | Multivariate analysis | Cancer therapies | Doxorubicin | Training | Bioindicators | Neutropenia | Risk groups | Cut-off | Melanoma | Rituximab | Data processing | Risk analysis | Gene expression | Survival | Patients | Vincristine | Lymphoma | Survival analysis | Chemotherapy | Monocytes | Lymphocytes B | Medical prognosis | Biomarkers | Lymphomas | Apoptosis | B-cell lymphoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
by Kochenderfer, James N and Somerville, Robert P.T and Lu, Tangying and Yang, James C and Sherry, Richard M and Feldman, Steven A and McIntyre, Lori and Bot, Adrian and Rossi, John and Lam, Norris and Rosenberg, Steven A
Molecular Therapy, ISSN 1525-0016, 10/2017, Volume 25, Issue 10, pp. 2245 - 2253
T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term... 
adoptive T cell therapy | chimeric antigen receptors | lymphoma | adoptive T cell therapy | REGRESSION | MEDICINE, RESEARCH & EXPERIMENTAL | CANCER | CHEMOTHERAPY | TRANSPLANTATION | TRIAL | MALIGNANCY | SINKS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CD19 | DISEASE | GENETICS & HEREDITY | LEUKEMIA | Immunotherapy, Adoptive - methods | Lymphoma, Large B-Cell, Diffuse - drug therapy | Immunoglobulin G - blood | Humans | Middle Aged | Male | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Cyclophosphamide - therapeutic use | Lymphoma, Large B-Cell, Diffuse - therapy | B-Lymphocytes - immunology | Immunoglobulin M - blood | Lymphoma, Large B-Cell, Diffuse - blood | Immunoglobulin A - blood | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Receptors, Antigen, T-Cell - immunology | T-Lymphocytes - immunology | Antigens, CD19 - immunology | Medical research | Antigens | Immunoglobulins | CD19 antigen | Research & development--R&D | Clinical trials | Infections | Lymphocytes T | Hypogammaglobulinemia | Patients | Lymphoma | Cyclophosphamide | Chemotherapy | Fludarabine | Lymphocytes B | Lymphocytes | Medical prognosis | Stem cells | Bone marrow | Remission | Lymphomas | Cancer | B-cell lymphoma | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
by Assouline, Sarit E and Nielsen, Torsten Holm and Yu, Stephen and Alcaide, Miguel and Chong, Lauren and MacDonald, David and Tosikyan, Axel and Kukreti, Vishal and Kezouh, Abbas and Petrogiannis-Haliotis, Tina and Albuquerque, Marco and Fornika, Daniel and Alamouti, Sepideh and Froment, Remi and Greenwood, Celia M.T and Oros, Kathleen Klein and Camglioglu, Errol and Sharma, Ayushi and Christodoulopoulos, Rosa and Rousseau, Caroline and Johnson, Nathalie and Crump, Michael and Morin, Ryan D and Mann, Koren K
Blood, ISSN 0006-4971, 07/2016, Volume 128, Issue 2, pp. 185 - 194
The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit... 
DEXAMETHASONE | CIRCULATING TUMOR DNA | RESPONSE CRITERIA | MEF2B MUTATIONS | II TRIAL | HISTONE DEACETYLASE INHIBITORS | HEMATOLOGY | EXPRESSION | SOMATIC MUTATIONS | CHEMOTHERAPY | TRANSPLANTATION | Panobinostat | Recurrence | MEF2 Transcription Factors - genetics | Lymphoma, Large B-Cell, Diffuse - drug therapy | Humans | Middle Aged | Male | Indoles - administration & dosage | MEF2 Transcription Factors - blood | Rituximab - administration & dosage | DNA, Neoplasm - blood | Lymphoma, Large B-Cell, Diffuse - blood | Hydroxamic Acids - administration & dosage | Adult | Female | Neoplasm Proteins - blood | Aged | DNA, Neoplasm - genetics | Mutation | Neoplasm Proteins - genetics | Lymphoma, Large B-Cell, Diffuse - genetics | Index Medicus | Abridged Index Medicus | 8 | Clinical Trials and Observations | 39 | 29
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Diffuse large B-cell lymphoma genotyping on the liquid biopsy
by Rossi, Davide and Diop, Fary and Spaccarotella, Elisa and Monti, Sara and Zanni, Manuela and Rasi, Silvia and Deambrogi, Clara and Spina, Valeria and Bruscaggin, Alessio and Favini, Chiara and Serra, Roberto and Ramponi, Antonio and Boldorini, Renzo and Foà, Robin and Gaidano, Gianluca
Blood, ISSN 0006-4971, 04/2017, Volume 129, Issue 14, pp. 1947 - 1957
Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is increasingly impelling in diffuse large B-cell lymphoma (DLBCL).... 
HETEROGENEITY | CIRCULATING TUMOR DNA | R-CHOP | RITUXIMAB | IBRUTINIB | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | HEMATOLOGY | SOMATIC MUTATIONS | DISCOVERY | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prospective Studies | Follow-Up Studies | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Genotyping Techniques | Lymphoma, Large B-Cell, Diffuse - blood | Biopsy | Vincristine - administration & dosage | Female | High-Throughput Nucleotide Sequencing | Mutation | Lymphoma, Large B-Cell, Diffuse - genetics | Doxorubicin - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
by Vaidya, R and Witzig, T.E
Annals of Oncology, ISSN 0923-7534, 11/2014, Volume 25, Issue 11, pp. 2124 - 2133
Rituximab has improved survival of diffuse large B-cell lymphoma (DLBCL) patients, yet 40% still die with standard RCHOP. Future DLBCL trials will combine a... 
Double hit | Large cell | Non-Hodgkin | Prognosis | Lymphoma | BCL-2 PROTEIN EXPRESSION | F-18 FDG-PET | R-CHOP | lymphoma | RANDOMIZED CONTROLLED-TRIAL | prognosis | CHEMOTHERAPY PLUS RITUXIMAB | FREE LIGHT-CHAIN | non-Hodgkin | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | double hit | NON-HODGKINS-LYMPHOMA | PREDICTS SURVIVAL | large cell | ELDERLY-PATIENTS | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Rituximab | In Situ Hybridization, Fluorescence | Treatment Outcome | Clinical Trials as Topic | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Vitamin D - blood | Proto-Oncogene Proteins c-myc - biosynthesis | Lymphoma, Large B-Cell, Diffuse - blood | Doxorubicin - analogs & derivatives | Monocytes - pathology | Lymphocyte Count | Vincristine - administration & dosage | Immunoglobulin Light Chains - blood | Lymphoma, Large B-Cell, Diffuse - genetics | Doxorubicin - administration & dosage | Index Medicus | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation
by Gupta, Mamta and Han, Jing Jing and Stenson, Mary and Maurer, Matthew and Wellik, Linda and Hu, Guangzhen and Ziesmer, Steve and Dogan, Ahmet and Witzig, Thomas E
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 12, pp. 2844 - 2853
Cytokines are deregulated in cancers and can contribute to tumor growth. In patients with diffuse large-cell lymphoma (DLBCL), we observed higher levels of... 
BREAST-CANCER CELLS | SURVIVIN EXPRESSION | INHIBITION | HEMATOLOGICAL MALIGNANCIES | STAT3 | NON-HODGKINS-LYMPHOMA | INTERLEUKIN-10 | HEMATOLOGY | INTESTINAL EPITHELIAL-CELLS | T-CELLS | CHEMOTHERAPY | Immunohistochemistry | Immunoprecipitation | Janus Kinase 2 - immunology | Enzyme-Linked Immunosorbent Assay | Humans | Kaplan-Meier Estimate | Interleukin-10 - blood | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Enzyme Activation - immunology | Biomarkers, Tumor - blood | Lymphoma, Large B-Cell, Diffuse - mortality | Receptors, Interleukin-10 - metabolism | Signal Transduction - immunology | Flow Cytometry | Lymphoma, Large B-Cell, Diffuse - blood | Janus Kinase 2 - metabolism | Lymphoma, Large B-Cell, Diffuse - immunology | RNA, Small Interfering | STAT3 Transcription Factor - immunology | STAT3 Transcription Factor - metabolism | Receptors, Interleukin-10 - immunology | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma
by Fang, Cheng and Zhu, Dan-Xia and Dong, Hua-Jie and Zhou, Zhi-Jian and Wang, Yin-Hua and Liu, Ling and Fan, Lei and Miao, Kou-Rong and Liu, Peng and Xu, Wei and Li, Jian-Yong
Annals of Hematology, ISSN 0939-5555, 4/2012, Volume 91, Issue 4, pp. 553 - 559
MicroRNAs (miRNAs) are regulatory RNA molecules that are deregulated in many disease types, including cancer. Recently, miRNAs have shown promise as markers... 
Oncology | Diffuse large B cell lymphoma | Medicine & Public Health | Hematology | Real-time quantitative RT-PCR | Serum microRNA | PLASMA | RNA | PROGNOSIS | DOWN-REGULATION | CHRONIC LYMPHOCYTIC-LEUKEMIA | CANCER-DIAGNOSIS | HEMATOLOGY | EXPRESSION | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Male | Biomarkers, Tumor - blood | Young Adult | Lymphoma, Large B-Cell, Diffuse - blood | Aged, 80 and over | Adult | Female | ROC Curve | Aged | Biomarkers, Tumor - genetics | MicroRNAs - blood | MicroRNAs - genetics | Lymphoma, Large B-Cell, Diffuse - genetics | MicroRNA | Tumors | Polymerase chain reaction | double prime B-cell lymphoma | biomarkers | Data processing | miRNA | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights